CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Reminder: On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the ch...
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
In July, all 5 CTS laboratories will convert from the current Grifols Ultrio Plus NAT triplex assay ...
On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Ris...